Fmr LLC Decreases Position in Encompass Health Co. (NYSE:EHC)

Fmr LLC cut its position in shares of Encompass Health Co. (NYSE:EHC) by 1.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,958,015 shares of the company’s stock after selling 28,866 shares during the period. Fmr LLC owned approximately 1.94% of Encompass Health worth $189,223,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Harbor Capital Advisors Inc. increased its position in shares of Encompass Health by 275.7% during the second quarter. Harbor Capital Advisors Inc. now owns 35,799 shares of the company’s stock worth $3,071,000 after acquiring an additional 26,270 shares during the period. QRG Capital Management Inc. lifted its holdings in shares of Encompass Health by 85.6% during the 2nd quarter. QRG Capital Management Inc. now owns 14,365 shares of the company’s stock valued at $1,232,000 after purchasing an additional 6,627 shares during the last quarter. SG Americas Securities LLC purchased a new position in Encompass Health during the 2nd quarter worth $2,204,000. Los Angeles Capital Management LLC increased its position in Encompass Health by 532.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company’s stock valued at $4,860,000 after buying an additional 42,338 shares in the last quarter. Finally, Pathstone Holdings LLC raised its stake in Encompass Health by 54.5% in the third quarter. Pathstone Holdings LLC now owns 21,022 shares of the company’s stock valued at $2,032,000 after buying an additional 7,412 shares during the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

EHC opened at $102.38 on Tuesday. The stock has a market cap of $10.31 billion, a P/E ratio of 24.73, a P/E/G ratio of 1.36 and a beta of 0.88. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a fifty day moving average price of $98.16 and a 200 day moving average price of $91.45. Encompass Health Co. has a 1 year low of $64.15 and a 1 year high of $104.55.

Encompass Health (NYSE:EHC) last posted its earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $0.86 EPS. Equities research analysts anticipate that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.17 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a yield of 0.66%. Encompass Health’s dividend payout ratio is currently 16.43%.

Wall Street Analyst Weigh In

EHC has been the topic of several recent analyst reports. Truist Financial restated a “buy” rating and set a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Royal Bank of Canada lifted their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Stephens reissued an “overweight” rating and issued a $105.00 target price on shares of Encompass Health in a research report on Tuesday, August 6th. Barclays boosted their price target on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Finally, UBS Group raised their price objective on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.